The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, II: Characteristics of Patients Enrolled and Not Enrolled: COMS Report No. 17 | Melanoma | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Scotto  JFraumeni  JFLee  JAH Melanomas of the eye and other noncutaneous sites: epidemiologic aspects.  J Natl Cancer Inst. 1976;56489- 491Google Scholar
Weve  H On diathermy in ophthalmic practice.  Trans Ophthalmol Soc U K. 1939;5943- 80Google Scholar
Meyer-Schwickerath  G The preservation of vision by treatment of intraocular tumors with light coagulation.  Arch Ophthalmol. 1961;6636- 44Google ScholarCrossref
Boniuk  MGirard  LJ Malignant melanoma of the choroid treated with photocoagulation, transscleral diathermy and implanted radon seeds.  Am J Ophthalmol. 1965;59212- 216Google Scholar
Stallard  HB Radiotherapy for malignant melanoma of the choroid.  Br J Ophthalmol. 1966;50147- 155Google ScholarCrossref
Lommatzsch  PK Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators.  Surv Ophthalmol. 1974;1985- 100Google Scholar
Peyman  GAAxelrod  AJGraham  RO Full-thickness eye wall resection: an experimental approach for treatment of choroidal melanoma: evaluation of cryotherapy, diathermy, and photocoagulation.  Arch Ophthalmol. 1974;91219- 222Google ScholarCrossref
Davidorf  FHMakley  TALang  JR Radiotherapy of malignant melanoma of the choroid.  Trans Am Acad Ophthalmol Otolaryngol. 1976;81849- 861Google Scholar
Sealy  Rle Roux  PLMRapley  FHering  EShackleton  DSevel  D The treatment of ophthalmic tumours with low-energy sources.  Br J Radiol. 1976;49551- 554Google ScholarCrossref
MacFaul  PA The place of radiotherapy in the treatment of uveal melanoma.  Doc Ophthalmol. 1980;5063- 69Google ScholarCrossref
Packer  SRotman  M Radiotherapy of choroidal melanoma with iodine-125.  Ophthalmology. 1980;87582- 590Google ScholarCrossref
Robertson  DMFountain  KSAnderson  JAPosthumus  GW Radioactive iodine-125 as a therapeutic radiation source for management of intraocular tumors.  Trans Am Ophthalmol Soc. 1981;79294- 306Google Scholar
Char  DHCastro  JR Helium ion therapy for choroidal melanoma.  Arch Ophthalmol. 1982;100935- 938Google ScholarCrossref
Gragoudas  ESGoitein  MVerhey  L  et al.  Proton beam irradiation of uveal melanoma: results of a 5½-year study.  Arch Ophthalmol. 1982;100928- 934Google ScholarCrossref
Shields  JAAugsburger  JJBrady  LWDay  JL Cobalt plaque therapy of posterior uveal melanoma.  Ophthalmology. 1982;891201- 1207Google ScholarCrossref
Zimmerman  LEMcLean  IWFoster  WD Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells?  Br J Ophthalmol. 1978;62420- 425Google ScholarCrossref
Zimmerman  LEMcLean  IW An evaluation of enucleation in the management of uveal melanoma.  Am J Ophthalmol. 1979;87741- 760Google Scholar
Collaborative Ocular Melanoma Study Group, The COMS randomized trial of iodine 125 brachytherapy for medium choroidal melanoma, III: initial mortality findings: COMS report No. 18.  Arch Ophthalmol. 2001;119969- 982Google ScholarCrossref
Char  DHSaunders  WCastro  JR  et al.  Helium ion therapy for choroidal melanoma.  Ophthalmology. 1983;901219- 1225Google ScholarCrossref
Gragoudas  ESGoitein  MSeddon  J  et al.  Preliminary results of proton beam irradiation of macular and paramacular melanomas.  Br J Ophthalmol. 1984;68479- 485Google ScholarCrossref
Gragoudas  ESSeddon  JGoitein  M  et al.  Current results of proton beam irradiation of uveal melanomas.  Ophthalmology. 1985;92284- 291Google ScholarCrossref
Seddon  JMGragoudas  ESAlbert  DMHsieh  C-CPolivogianis  LFriedenberg  GR Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation.  Am J Ophthalmol. 1985;99282- 290Google Scholar
Lommatzsch  PK β-irradiation of choroidal melanoma with 106Ru/106Rh applicators: 16 years' experience.  Arch Ophthalmol. 1983;101713- 717Google ScholarCrossref
Packer  SRotman  MSalanitro  P Iodine-125 irradiation of choroidal melanoma: clinical experience.  Ophthalmology. 1984;911700- 1708Google ScholarCrossref
Augsburger  JJGamel  JWSardi  VFGreenberg  RAShields  JABrady  LW Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body.  Arch Ophthalmol. 1986;104655- 661Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, I: characteristics of patients enrolled and not enrolled: COMS report No.9.  Am J Ophthalmol. 1998;125767- 778Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, II: initial mortality findings: COMS report No.10.  Am J Ophthalmol. 1998;125779- 796Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma, III: local complications and observations following enucleation: COMS report No. 11.  Am J Ophthalmol. 1998;126362- 372Google ScholarCrossref
Earle  JDKline  RWRobertson  DM Selection of iodine 125 for the Collaborative Ocular Melanoma Study.  Arch Ophthalmol. 1987;105763- 764Google ScholarCrossref
Straatsma  BRFine  SLEarle  JDHawkins  BSDiener-West  MMcLaughlin  JACollaborative Ocular Melanoma Study Research Group, Enucleation versus plaque irradiation for choroidal melanoma.  Ophthalmology. 1988;951000- 1004Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, Design and methods of a clinical trial for a rare condition: the Collaborative Ocular Melanoma Study: COMS report No. 3.  Controlled Clin Trials. 1993;14362- 391Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, Collaborative Ocular Melanoma Study (COMS) randomized trial of I 125 brachytherapy for medium choroidal melanoma, I: visual acuity 3 years following I 125 brachytherapy for choroidal melanoma.  Ophthalmology. 2001;108348- 366Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study: COMS report No.6.  Am J Ophthalmol. 1998;125745- 766Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study: COMS report No. 1.  Arch Ophthalmol. 1990;1081268- 1273Google ScholarCrossref
Melia  BMDiener-West  M Modeling interrater agreement for pathologic features of choroidal melanoma. Lange  NRyan  LBillard  LBrillinger  DConquest  LGreenhouse  Jeds. Case Studies in Biometry. New York, NY JohnWiley & Sons Inc1994;323- 338Google Scholar
Collaborative Ocular Melanoma Study Group, Echography (ultrasound) procedures for the Collaborative Ocular Melanoma Study (COMS): report No. 12.  J Ophthalmic Nurs Technol. 1999;18 (Pt I) 143- 149Pt II219- 232Google Scholar
Collaborative Ocular Melanoma Study Group, COMS Manual of Procedures.  Springfield, Va National Technical Information Service1995;AccessionNo. PB95-179693.
Collaborative Ocular Melanoma Study Group, COMS Study Forms Book.  Springfield, Va National Technical Information Service1991;AccessionNo. PB91-217315.
Snedecor  GWCochran  WG Statistical Methods. 7th Ames Iowa State University Press1980;144- 145
Armitage  PBerry  G Statistical Methods in Medical Research. 2nd Boston, Mass Blackwell Scientific Publications Inc1987;372- 374
Collaborative Ocular Melanoma Study Group, Sociodemographic and clinical predictors of patient participation in two randomized trials: findings from the Collaborative Ocular Melanoma Study: COMS report No. 7.  Controlled Clin Trials. In press.Google Scholar
Egan  KMSeddon  JMGlynn  RJGragoudas  ESAlbert  DM Epidemiologic aspects of uveal melanoma.  Surv Ophthalmol. 1988;32239- 251Google ScholarCrossref
Wells  CGBradford  RHFish  GEStraatsma  BRHawkins  BSfor the COMS Group, Choroidal melanomas in American Indians.  Arch Ophthalmol. 1996;1141017- 1018Google ScholarCrossref
Schachat  APMarkowitz  JAHawkins  BSFine  SLCollaborative Ocular Melanoma Study Group, Nonocular cancers in patients with choroidal melanoma [letter].  Ophthalmology. 1990;97837- 838Google ScholarCrossref
Char  DHCastro  JRQuivey  JMPhillips  TLIrvine  ARStone  RDKroll  S Uveal melanoma radiation: 125I brachytherapy versus helium ion irradiation.  Ophthalmology. 1989;961708- 1715Google ScholarCrossref
Char  DHQuivey  JMCastro  JRKroll  SPhillips  T Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma: a prospective, randomized, dynamically balanced trial.  Ophthalmology. 1993;1001547- 1554Google ScholarCrossref
Char  DHKroll  SQuivey  JMCastro  J Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.  Br J Ophthalmol. 1996;80117- 124Google ScholarCrossref
Bornfeld  NChauvel  PSauerwein  W  et al.  Metastatic disease, eye retention and visual function in conservative treatment of uveal melanoma.  Front Radiat Ther Oncol. 1997;3097- 110Google Scholar
Quivey  JMAugsburger  JSnelling  LBrady  LW 125I plaque therapy for uveal melanoma: analysis of the impact of time and dose factors on local control.  Cancer. 1996;772356- 2362Google ScholarCrossref
Fontanesi  JMeyer  DXu  STai  D Treatment of choroidal melanoma with I 125 plaque.  Int J Radiat Oncol Biol Phys. 1993;26619- 623Google ScholarCrossref
Packer  SStoller  SLesser  MLMandel  FSFinger  PT Long-term results of iodine 125 irradiation of uveal melanoma.  Ophthalmology. 1992;99767- 774Google ScholarCrossref
Meyer  LWagner  JPBenichou  CHermsdorff  CSahel  JA Curiethérapie à l'iode 125 des mélanomeschoroïdiens: intérêts de la technique et premiers résultats.  J Fr Ophtalmol. 1996;19755- 760Google Scholar
Garretson  BRRobertson  DMEarle  JD Choroidal melanoma treatment with iodine 125 brachytherapy.  Arch Ophthalmol. 1987;1051394- 1397Google ScholarCrossref
Hill  JCSealy  RShackleton  D  et al.  Improved iodine-125 plaque design in the treatment of choroidal malignant melanoma.  Br J Ophthalmol. 1992;7691- 94Google ScholarCrossref
Kreissig  IRose  DJost  B Long-term follow-up of iodine-125 brachytherapy for choroidal melanoma, part I: anatomical results and life expectancy.  Eur J Ophthalmol. 1993;3121- 126Google Scholar
Hunter  CPFrelick  RWFeldman  AR  et al.  Selection factors in clinical trials: results from the Community Clinical Oncology Program physician's patient log.  Cancer Treat Rep. 1987;71559- 565Google Scholar
Hutchins  LFUnger  JMCrowley  JJColtman  CAAlbain  KS Underrepresentation of patients 65 years of age or older in cancer treatment trials.  N Engl J Med. 1999;3412061- 2067Google ScholarCrossref
Begg  CCho  MEastwood  S  et al.  Improving the quality of reporting of randomized controlled trials: the CONSORT statement.  JAMA. 1996;276637- 639Google ScholarCrossref
CASS Principal Investigators and Their Associates, Coronary Artery Surgery Study (CASS): a randomized trial of coronary artery surgery bypass surgery: comparability of entry characteristics and survival in randomized patients and nonrandomized patients meeting randomization criteria.  J Am Coll Cardiol. 1984;3114- 128Google ScholarCrossref
Chaitman  BRRyan  TJKronmal  RAFoster  EDFrommer  PLKillip  Tand CASS Investigators, Coronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients.  J Am Coll Cardiol. 1990;161071- 1078Google ScholarCrossref
Collaborative Ocular Melanoma Study Group, Mortality in patients with small choroidal melanoma: COMS report No. 4.  Arch Ophthalmol. 1997;115886- 893Google ScholarCrossref
Clinical Sciences
July 2001

The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma, II: Characteristics of Patients Enrolled and Not Enrolled: COMS Report No. 17

Arch Ophthalmol. 2001;119(7):951-965. doi:10.1001/archopht.119.7.951

Objectives  To describe characteristics of patients evaluated for the Collaborative Ocular Melanoma Study (COMS) randomized clinical trial of iodine 125 brachytherapy for choroidal melanoma by enrollment status, and to compare characteristics of patients enrolled with those of patients with tumors of eligible size who did not enroll in order to assess the extent to which findings from the clinical trial can be generalized to future patients.

Methods  For all patients diagnosed with choroidal melanoma and evaluated for the clinical trial at COMS centers from November 1986 through July 31, 1998, selected data were transmitted to the COMS Coordinating Center, Baltimore, Md, where they were integrated and analyzed. Data included ophthalmic and medical history, examination findings, and visual acuity measurements recorded prior to enrollment; standardized A- and B-scan echographic examination findings; and wide-angle fundus photographs and fluorescein angiograms.

Results  Of 8712 patients with choroidal melanoma, 5046 had tumors of eligible size; of these, 2882 (57%) were eligible for enrollment, and 1317 (46% of eligible patients, 26% of patients with tumors of eligible size) enrolled. Most differences between eligible and ineligible patients corresponded to eligibility and exclusion criteria. However, ineligible patients were older and had thicker tumors than eligible patients. Eligible patients who enrolled were slightly older and had larger tumors than those who did not enroll. Nearly half (48%) of enrolled patients had choroidal melanoma with the apex located temporal to the fovea, compared with 40% of eligible patients not enrolled and 29% of ineligible patients.

Conclusions  This trial was designed to yield internally valid treatment comparisons through random assignment to treatment at time of enrollment. Information from this and other studies document that enrolled patients were similar to other patients with choroidal melanoma who were treated with 125I brachytherapy. These findings support the external validity of the trial and applicability of treatment findings to all patients who meet the criteria used to judge eligibility for the trial.